Article in The Journal of experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors at 2 institutions in 1 country.
Vincent FregonaUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0003-4857-1737
Manon BayetUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0003-0145-367X
Mathieu BouttierUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0003-0136-3439
Laetitia LargeaudUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0001-5341-5427
Camille HamelleUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0009-0009-2737-775X
Laura A JamrogUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0003-2288-0806
Naïs PradeUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0009-0006-1204-6809
Stéphanie LagardeUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0009-0004-1817-3855
Sylvie HebrardUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0009-0005-1664-2598
Isabelle LuquetUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0001-7891-5727
Véronique Mansat-De MasUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0003-1878-9129
Marie NollaUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0003-2528-9704
Marlène PasquetUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0001-6919-8383
Christine DidierUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0003-3979-0743
Ahmed Amine KhamlichiInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0002-6523-2035
Cyril BroccardoUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0003-3016-6549
Éric Delabesse *Université de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0002-0928-0753
Stéphane J C Mancini *Universit é de Rennes , Etablissement Français du Sang, Inserm, MOBIDIC-UMR_S 1236 , Rennes, France.ORCID 0000-0001-9255-4606
Bastien GerbyUniversité de Toulouse, Inserm, Centre Nationale de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse , Toulouse, France.ORCID 0000-0002-2657-4200
Université Toulouse III - Paul Sabatier · FRInserm · FR
Funding
Agence Nationale de la Recherche ANR-18-CE13-0002-01CassandraCentre National de la Recherche ScientifiqueConstance la petite guerrière astronauteFondation ARC pour la Recherche sur le Cancer PJA-20181207977Institut National de la Santé et de la Recherche MédicaleInstitut National du Cancer INCa-2020-096Laurette FugainLes 111 des artsLigue Contre le Cancer
6 · The paper itself
Abstract
B cell acute lymphoblastic leukemia (B-ALL) is a multistep disease characterized by the hierarchical acquisition of genetic alterations. However, the question of how a primary oncogene reprograms stem cell-like properties in committed B cells and leads to a preneoplastic population remains unclear. Here, we used the PAX5::ELN oncogenic model to demonstrate a causal link between the differentiation blockade, the self-renewal, and the emergence of preleukemic stem cells (pre-LSCs). We show that PAX5::ELN disrupts the differentiation of preleukemic cells by enforcing the IL7r/JAK-STAT pathway. This disruption is associated with the induction of rare and quiescent pre-LSCs that sustain the leukemia-initiating activity, as assessed using the H2B-GFP model. Integration of transcriptomic and chromatin accessibility data reveals that those quiescent pre-LSCs lose B cell identity and reactivate an immature molecular program, reminiscent of human B-ALL chemo-resistant cells. Finally, our transcriptional regulatory network reveals the transcription factor EGR1 as a strong candidate to control quiescence/resistance of PAX5::ELN pre-LSCs as well as of blasts from human B-ALL.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL. · full record | OpenQuestion